The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...
Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback